Difference between revisions of "Penpulimab (Anniko)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Hodgkin lymphoma|" to "[[Classical Hodgkin lymphoma|") |
m |
||
| Line 7: | Line 7: | ||
==History of changes in NMPA indication== | ==History of changes in NMPA indication== | ||
| − | *2021-08-05: | + | *2021-08-05: Initial approval for treatment of patients with relapsed or refractory ("r/r") [[Classical Hodgkin lymphoma|classic Hodgkin’s lymphoma ("cHL")]] after at least second-line systemic chemotherapy treatment. |
| + | *2023-01-15: Approved in combination with chemotherapy as the first-line treatment of locally advanced or metastatic [[Non-small cell lung cancer, squamous|squamous non-small cell lung cancer (sq-NSCLC)]]. ''(Based on AK105-302)'' | ||
==Also known as== | ==Also known as== | ||
| Line 17: | Line 18: | ||
[[Category:Anti-PD-1 antibodies]] | [[Category:Anti-PD-1 antibodies]] | ||
[[Category:Classical Hodgkin lymphoma medications]] | [[Category:Classical Hodgkin lymphoma medications]] | ||
| − | [[Category:NMPA approved | + | [[Category:NMPA approved in 2021]] |
Revision as of 12:39, 26 June 2023
Note: Penpulimab is approved in China, but does not appear to have a brand name at this time.
Mechanism of action
PD-1 inhibitor
Diseases for which it is used
History of changes in NMPA indication
- 2021-08-05: Initial approval for treatment of patients with relapsed or refractory ("r/r") classic Hodgkin’s lymphoma ("cHL") after at least second-line systemic chemotherapy treatment.
- 2023-01-15: Approved in combination with chemotherapy as the first-line treatment of locally advanced or metastatic squamous non-small cell lung cancer (sq-NSCLC). (Based on AK105-302)
Also known as
- Code name: AK105